These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 36283897)

  • 1. Immunogenicity and safety of two novel human papillomavirus 4- and 9-valent vaccines in Chinese women aged 20-45 years: A randomized, blinded, controlled with Gardasil (type 6/11/16/18), phase III non-inferiority clinical trial.
    Shu Y; Yu Y; Ji Y; Zhang L; Li Y; Qin H; Huang Z; Ou Z; Huang M; Shen Q; Li Z; Hu M; Li C; Zhang G; Zhang J
    Vaccine; 2022 Nov; 40(48):6947-6955. PubMed ID: 36283897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9-14 years versus an established quadrivalent HPV vaccine in women aged 15-26 years in India: a randomised, active-controlled, multicentre, phase 2/3 trial.
    Sharma H; Parekh S; Pujari P; Shewale S; Desai S; Bhatla N; Joshi S; Pimple S; Kawade A; Balasubramani L; Thomas A; Suri V; Lalwani S; Uday R; Kamath V; Mandal R; Rajeswar A; Peedicayil A; Poli UR; Banerjee D; Sankaranarayanan R; Basu P; Muwonge R; Gairola S; Dogar V; Rao H; Shaligram U
    Lancet Oncol; 2023 Dec; 24(12):1321-1333. PubMed ID: 37949086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial.
    Huh WK; Joura EA; Giuliano AR; Iversen OE; de Andrade RP; Ault KA; Bartholomew D; Cestero RM; Fedrizzi EN; Hirschberg AL; Mayrand MH; Ruiz-Sternberg AM; Stapleton JT; Wiley DJ; Ferenczy A; Kurman R; Ronnett BM; Stoler MH; Cuzick J; Garland SM; Kjaer SK; Bautista OM; Haupt R; Moeller E; Ritter M; Roberts CC; Shields C; Luxembourg A
    Lancet; 2017 Nov; 390(10108):2143-2159. PubMed ID: 28886907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women.
    Ruiz-Sternberg ÁM; Moreira ED; Restrepo JA; Lazcano-Ponce E; Cabello R; Silva A; Andrade R; Revollo F; Uscanga S; Victoria A; Guevara AM; Luna J; Plata M; Dominguez CN; Fedrizzi E; Suarez E; Reina JC; Ellison MC; Moeller E; Ritter M; Shields C; Cashat M; Perez G; Luxembourg A
    Papillomavirus Res; 2018 Jun; 5():63-74. PubMed ID: 29269325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expanded strain coverage for a highly successful public health tool: Prophylactic 9-valent human papillomavirus vaccine.
    Zhang Z; Zhang J; Xia N; Zhao Q
    Hum Vaccin Immunother; 2017 Oct; 13(10):2280-2291. PubMed ID: 28699820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27-45 years of age compared to women 16-26 years of age: An open-label phase 3 study.
    Joura EA; Ulied A; Vandermeulen C; Rua Figueroa M; Seppä I; Hernandez Aguado JJ; Ahonen A; Reich O; Virta M; Perino A; Peris Tuser M; Peters K; Origoni M; Raspagliesi F; Tjalma WAA; Tummers P; Woelber L; Nieminen P; van Damme P; Sehouli J; Fiol Ruiz G; Brucker S; Fehm T; Cheon K; Rawat S; Luxembourg A; Wittke F
    Vaccine; 2021 May; 39(20):2800-2809. PubMed ID: 33676783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil® in 9-15-Year-Old Girls.
    Vesikari T; Brodszki N; van Damme P; Diez-Domingo J; Icardi G; Petersen LK; Tran C; Thomas S; Luxembourg A; Baudin M
    Pediatr Infect Dis J; 2015 Sep; 34(9):992-8. PubMed ID: 26090572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Head-to-head immunogenicity comparison of an Escherichia coli-produced 9-valent human papillomavirus vaccine and Gardasil 9 in women aged 18-26 years in China: a randomised blinded clinical trial.
    Zhu FC; Zhong GH; Huang WJ; Chu K; Zhang L; Bi ZF; Zhu KX; Chen Q; Zheng TQ; Zhang ML; Liu S; Xu JB; Pan HX; Sun G; Zheng FZ; Zhang QF; Yi XM; Zhuang SJ; Huang SJ; Pan HR; Su YY; Wu T; Zhang J; Xia NS
    Lancet Infect Dis; 2023 Nov; 23(11):1313-1322. PubMed ID: 37475116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase III clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men.
    Van Damme P; Meijer CJLM; Kieninger D; Schuyleman A; Thomas S; Luxembourg A; Baudin M
    Vaccine; 2016 Jul; 34(35):4205-4212. PubMed ID: 27354258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa.
    Mugo N; Ansah NA; Marino D; Saah A; Garner EI
    Hum Vaccin Immunother; 2015; 11(6):1323-30. PubMed ID: 25912475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and safety of one-dose human papillomavirus vaccine compared with two or three doses in Tanzanian girls (DoRIS): an open-label, randomised, non-inferiority trial.
    Watson-Jones D; Changalucha J; Whitworth H; Pinto L; Mutani P; Indangasi J; Kemp T; Hashim R; Kamala B; Wiggins R; Songoro T; Connor N; Mbwanji G; Pavon MA; Lowe B; Mmbando D; Kapiga S; Mayaud P; de SanJosé S; Dillner J; Hayes RJ; Lacey CJ; Baisley K
    Lancet Glob Health; 2022 Oct; 10(10):e1473-e1484. PubMed ID: 36113531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of a 9-valent HPV vaccine in females 12-26 years of age who previously received the quadrivalent HPV vaccine.
    Garland SM; Cheung TH; McNeill S; Petersen LK; Romaguera J; Vazquez-Narvaez J; Bautista O; Shields C; Vuocolo S; Luxembourg A
    Vaccine; 2015 Nov; 33(48):6855-64. PubMed ID: 26411885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of Innovax bivalent human papillomavirus vaccine in girls 9-14 years of age: Interim analysis from a phase 3 clinical trial.
    Zaman K; Schuind AE; Adjei S; Antony K; Aponte JJ; Buabeng PB; Qadri F; Kemp TJ; Hossain L; Pinto LA; Sukraw K; Bhat N; Agbenyega T
    Vaccine; 2024 Apr; 42(9):2290-2298. PubMed ID: 38431444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of a nine-valent human papillomavirus vaccine in Vietnamese males and females (9 to 26 years of age): an open-label, phase 3 trial.
    Thiem VD; Quang ND; Tuan NH; Cheon K; Gallagher N; Luxembourg A; Group T; Badshah C
    Hum Vaccin Immunother; 2021 Jul; 17(7):1980-1985. PubMed ID: 33844623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of quadrivalent and 9-valent human papillomavirus vaccines in Indian clinical trial participants.
    Garland SM; Anagani M; Bhatla N; Chatterjee S; Lalwani S; Ross C; Group T; Lin J; Luxembourg A; Walia A; Tu Y
    Hum Vaccin Immunother; 2022 Nov; 18(6):2105067. PubMed ID: 35997582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and safety of the 9-valent human papillomavirus vaccine in Chinese females 9-45 years of age: A phase 3 open-label study.
    Lv H; Wang S; Liang Z; Yu W; Yan C; Chen Y; Hu X; Fu R; Zheng M; Group T; Luxembourg A; Liao X; Chen Z
    Vaccine; 2022 May; 40(23):3263-3271. PubMed ID: 35487814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim analysis after 8 years of follow-up.
    Olsson SE; Restrepo JA; Reina JC; Pitisuttithum P; Ulied A; Varman M; Van Damme P; Moreira ED; Ferris D; Block S; Bautista O; Gallagher N; McCauley J; Luxembourg A
    Papillomavirus Res; 2020 Dec; 10():100203. PubMed ID: 32659510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study.
    Cody P; Tobe K; Abe M; Elbasha EH
    BMC Infect Dis; 2021 Jan; 21(1):11. PubMed ID: 33407188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years.
    Einstein MH; Baron M; Levin MJ; Chatterjee A; Edwards RP; Zepp F; Carletti I; Dessy FJ; Trofa AF; Schuind A; Dubin G;
    Hum Vaccin; 2009 Oct; 5(10):705-19. PubMed ID: 19684472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial.
    Leung TF; Liu AP; Lim FS; Thollot F; Oh HM; Lee BW; Rombo L; Tan NC; Rouzier R; Friel D; De Muynck B; De Simoni S; Suryakiran P; Hezareh M; Folschweiller N; Thomas F; Struyf F
    Hum Vaccin Immunother; 2015; 11(7):1689-702. PubMed ID: 26062002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.